GP
PHAT icon

Greenline Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Greenline Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$4.06K – 601
2024
Q4 		$4.06K Buy
+500
New +$6.19K ﹤0.01% 230

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Greenline Partners's PHAT Position: Q1 2025 in Review

Greenline Partners sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 500 shares — an estimated $4.06K sold.

Greenline Partners first reported a position in PHAT in Q4 2024 and held it in 1 quarter. The position peaked at $4.06K in Q4 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Greenline Partners reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Greenline Partners sold 500 Phathom Pharmaceuticals shares in Q1 2025, an estimated $4.06K.
  • Greenline Partners first reported a position in Phathom Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Greenline Partners's Phathom Pharmaceuticals position peaked at $4.06K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Greenline Partners's 13F filing for Q1 2025, filed 15 May 2025.